Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Cancer chronic myeloid leukemia

Cancers Multiple myeloma Non-Hodgkin s lymphoma Hodgkin s disease Acute myeloid leukemia Neuroblastoma Germ cell tumors Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Myelodysplastic syndrome Myeloproliferative disorders Non-Hodgkin s lymphoma Hodgkin s disease Chronic lymphocytic leukemia Multiple myeloma... [Pg.1448]

Quintas-Cardama A, Kantaijian H, Garcia-Manero G O Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. (2007) Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109 248-255. [Pg.177]

Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA. Long-term snrvival estimates for ima-tinib versus interferon-alpha pins low-dose cytara-bine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004 101 2284-92. [Pg.53]

Interferon alfa versus chemotherapy for chronic myeloid leukemia a meta-analysis of seven randomized trials Chronic Myeloid Leukemia Trialists Collaborative Group. J Natl Cancer Inst 1997 89 1616-1620. [Pg.145]

Created by the merger of Ciba and Sandoz, it makes Diovan for hypertension, Gleevec for chronic myeloid leukemia, Zometa for cancer complications, Sandostatin for excess production of growth hormone, Femara for breast cancer, and En-ablex for an overactive bladder. [Pg.211]

In June 1999, phase I clinical trials of OTI-010 were initiated in cancer patients receivingchemotherapy and HSC transplantation for the treatment of high-risk hematological malignancies (including acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and non-Hodgkin s lymphoma). The multicenter studies, conducted in seven US and European cancer centers, showed OTI-010 to be safe and efficacious, with 52% of patients ( 40 patients) responding positively to the therapy [327297], [495015]. [Pg.65]

Produced by recombinant DNA technology, IFN-a-2a is used for the treatment of chronic myeloid leukemia, Kaposi sarcoma, lymphoma, hairy cell leukemia, hepatitis B and C and cancer of the skin and kidney. It can only be administered by injection or into the bloodstream, and the most common method is subcutaneous injection. This cytokine can be injected every day however, commonly it is... [Pg.44]

Shah, N. P., Nicoll, J., Nagar, B., et al. (2002) Multiple BRC-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125. [Pg.39]

Milojkovic D et al (2009) Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Cancer Res 15 7519-7527... [Pg.242]

Boddy AV et al (2007) Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin Cancer Res 13 4164—4169... [Pg.243]

Pricl S, Fermeglia M, Ferrone M, Tamborini E (2005) T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib insights from a computational study. Mol Cancer Ther 4(8)4167-1174... [Pg.112]

Cells and cell lines NIH 3T3, mouse embryonic fibroblasts K562, human chronic myeloid leukemia MDA-MB-231, human breast cancer MiaPaCa2, human pancreatic cancer n/d, not determined NSCLC, nonsmall cell lung cancer p-, phosphporylated form of a protein RB, retinoblastoma protein. [Pg.148]

Compared with untreated patients and patients treated with busulfan or hydroxyurea, interferon alfa produced a significantly higher frequency of clonal aberrant cytogenetic abnormalities and chronic clonal evolution in patients with chronic myeloid leukemia (386). However, the possible role of interferon alfa in the secondary occurrence of hematological malignancies is purely speculative. Only isolated cases of myeloproliferative syndrome, leukemia, or lymphoma have been attributed to interferon alfa (SED-13, 1098) (SEDA-20, 331) (SEDA-21, 373). There was no increased incidence of second cancers in patients treated for hairy cell leukemia (SEDA-20, 331). [Pg.1816]

Jadoul M. Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer 1999 85(12) 2669-70. [Pg.1826]

Kozuch P, Talpaz M, Faded S, O Brien S, Freireich EJ, Kantarjian H. Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha a synergistic correlation Cancer 2000 89(7) 1482-9. [Pg.1827]

See other pages where Cancer chronic myeloid leukemia is mentioned: [Pg.383]    [Pg.3]    [Pg.383]    [Pg.3]    [Pg.190]    [Pg.1194]    [Pg.4]    [Pg.506]    [Pg.130]    [Pg.4]    [Pg.124]    [Pg.148]    [Pg.1165]    [Pg.37]    [Pg.246]    [Pg.92]    [Pg.29]    [Pg.1282]    [Pg.253]    [Pg.4]    [Pg.50]    [Pg.104]    [Pg.479]    [Pg.29]    [Pg.171]    [Pg.1194]    [Pg.235]    [Pg.838]    [Pg.1562]    [Pg.1562]    [Pg.1326]    [Pg.695]    [Pg.388]    [Pg.108]    [Pg.117]    [Pg.736]   
See also in sourсe #XX -- [ Pg.253 , Pg.254 , Pg.255 , Pg.256 , Pg.257 , Pg.258 , Pg.259 , Pg.260 , Pg.261 , Pg.262 , Pg.263 , Pg.264 ]



SEARCH



Cancer leukemia

Chronic myeloid

Leukemia chronic

Myeloid

Myeloid leukemia

Myeloid leukemia chronic

© 2024 chempedia.info